Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? [3]

Annals of Neurology

Volumn 47, Issue 5, 2000, Pages 682-683

  Herrlinger, U ^a   Weller, M ^a   Dichgans, J ^a   Melms, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ADULT; AGED; AUTOIMMUNE DISEASE; BRAIN LYMPHOMA; CENTRAL NERVOUS SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

EID: 0034018455     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200005)47:5<682::aid-ana24>3.0.co;2-z     Document Type: Letter

References (5)

1. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-745
2. Confavreux C, Saddier P, Grimaud J, et al. Risk of cancer from azathioprine therapy in multiple sclerosis. Neurology 1996;46: 1607-1612
3. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-1252
4. Palace BM, Newsom-Davis J, Lecky B, Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50: 1778-1783
5. Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17: 238-242